The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022).
 
Federica Pecci
No Relationships to Disclose
 
Biagio Ricciuti
No Relationships to Disclose
 
Joao Victor Machado Alessi
No Relationships to Disclose
 
Adriana Paula de Castro Barrichello
No Relationships to Disclose
 
Victor R. Vaz
No Relationships to Disclose
 
Giuseppe Lamberti
No Relationships to Disclose
 
Jessica Kim Lee
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Alexa Betzig Schrock
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine; Roche
 
Vikas K Goel
Employment - Turning Point Therapeutics
Stock and Other Ownership Interests - eFFECTOR Therapeutics; Turning Point Therapeutics
Research Funding - Turning Point Therapeutics
 
Zach Zimmerman
Employment - Turning Point Therapeutics
Stock and Other Ownership Interests - Turning Point Therapeutics
 
Magda Bahcall
Stock and Other Ownership Interests - Babson Diagnostics (I); Madrigal Pharmaceuticals (I); NexImmune (I)
Speakers' Bureau - Flatiron Health (I); GlaxoSmithKline (I); Janssen (I); Vizient (I)
Research Funding - Janssen
 
Pasi A. Janne
Stock and Other Ownership Interests - Gatekeeper Pharmaceuticals; Loxo
Consulting or Advisory Role - Abbvie; Accutar Biotech; Allorion Therapeutics; Araxes Pharma; AstraZeneca; Bayer; Biocartis; Biocartis; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Lilly; LOXO; Merrimack; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche/Genentech; Sanofi; SFJ Pharmaceuticals Group; Silicon Therapeutics; Syndax; Takeda; Transcenta; Voronoi Health Analytics
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly; Puma Biotechnology; Revolution Medicines; Takeda
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp. I receive post-marketing royalties from this invention
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; Achilles Therapeutics; Archer; ARIAD; AstraZeneca; AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; EMD Serono; Foundation Medicine; Genentech; Gilead Sciences; Gritstone Bio; Hengrui Therapeutics; Instil Bio; Janssen Oncology; Maverick Therapeutics; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Panasonic; Pfizer; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst)